Reglan and Tardive Dyskinesia: What New Jersey Patients Should Know
From General Health Awareness to Specific Medication Risks
If you or a loved one has taken Reglan (metoclopramide) for a gastrointestinal condition, you may have heard about the risk of tardive dyskinesia—a neurological disorder causing involuntary movements. This concern has grown as medical research has clarified the long-term effects of the drug. Building on decades of pharmacovigilance, this guide explains what New Jersey residents need to know about Reglan, tardive dyskinesia symptoms, and how to approach care discussions with your healthcare provider.
Reglan and Tardive Dyskinesia: The Medical Evidence
Reglan (metoclopramide) is a prescription medication approved for short-term use in adults with symptomatic gastroesophageal reflux (4 to 12 weeks) and for relief of symptoms in acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The drug carries a boxed warning stating that metoclopramide, including Reglan, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). TD is characterized by involuntary, repetitive movements of the face, tongue, trunk, and extremities, which may be disfiguring and can persist even after the drug is discontinued (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with longer duration of treatment and higher total cumulative dosage of metoclopramide (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the label instructs prescribers to use the drug for the shortest duration necessary and to periodically reassess the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic gastroesophageal reflux, the maximum approved treatment duration is 12 weeks; for diabetic gastroparesis, total treatment duration should also be limited to 12 weeks, and if longer use is unavoidable, routine monitoring for signs of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan tablets are not recommended for pediatric patients due to the risk of TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The mechanistic pathway linking metoclopramide to TD involves dopamine D2 receptor blockade in the basal ganglia, which can lead to supersensitivity of dopamine receptors and subsequent involuntary movements. The label notes that metoclopramide may suppress or partially suppress the signs of TD, potentially delaying diagnosis by masking the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Clinical presentation of TD typically includes orofacial movements such as lip smacking, chewing, tongue protrusion, and grimacing, as well as choreiform movements of the limbs and trunk. Diagnosis is based on clinical history and physical examination, with no definitive laboratory tests available.
Statute of Limitations for Reglan Claims in New Jersey
From a risk perspective, the adequacy of warnings regarding Reglan and TD is a central issue. The boxed warning explicitly states the risk, but many patients were prescribed Reglan for extended periods beyond the recommended 12-week limit, often for off-label uses or without adequate monitoring. The timeline between exposure and documented harm can vary widely; TD may develop after months or years of use, and symptoms can appear even after the drug is discontinued. This latency complicates the determination of when the statute of limitations begins to run in legal claims. In New Jersey, the statute of limitations for personal injury claims, including those related to prescription drug side effects, is generally two years from the date the injury was discovered or reasonably should have been discovered. For TD, the discovery date may be when a patient first notices involuntary movements or when a physician diagnoses the condition. However, because TD can be subtle initially and may be misattributed to other causes, the exact trigger date can be contested. Patients who took Reglan for longer than 12 weeks and later developed TD may have claims against the manufacturer for failure to adequately warn about the risk of prolonged use. Settlement considerations for affected patients include the severity of TD symptoms, the duration of Reglan use, the presence of other risk factors (such as older age or female sex), and the strength of evidence linking the drug to the injury. The boxed warning provides clear documentation of the known risk, which can support claims that the manufacturer had a duty to warn. However, patients must also demonstrate that their TD was caused by Reglan and not by another medication or underlying condition. The cumulative dosage and treatment duration are key factors in establishing causation. Patients in New Jersey should be aware that the statute of limitations may begin running at the time of diagnosis or when symptoms become noticeable, not necessarily when the drug was prescribed. Legal advice should be sought promptly to preserve the right to file a claim. The evidence from the FDA-approved label underscores that Reglan use should be limited to short-term therapy, and any use beyond 12 weeks increases the risk of TD. This information is critical for both medical management and legal evaluation of potential claims.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Reglan-related tardive dyskinesia claims in New Jersey?
In New Jersey, the statute of limitations for personal injury claims, including those related to prescription drug side effects like tardive dyskinesia, is generally two years from the date the injury was discovered or reasonably should have been discovered. For TD, this may be when symptoms first appear or when a diagnosis is made. It is important to seek legal advice promptly to preserve your right to file a claim.
Can I file a lawsuit if I developed tardive dyskinesia after taking Reglan for more than 12 weeks?
Yes, you may have a claim against the manufacturer for failure to adequately warn about the risk of prolonged use. The FDA label explicitly states that Reglan should not be used for more than 12 weeks due to the risk of TD. However, you must demonstrate that your TD was caused by Reglan and not another factor. Consult an attorney to evaluate your case.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Community Resource & Benefit Desk
Request archival records or inquire about member-exclusive transition and benefit programs.